PhD Studentship: Linking Myeloma Therapies, the Microbiome, and Immune Defence

Each year, approximately 6,000 people in the UK are diagnosed with multiple myeloma. Despite advances in therapy, infections remain a leading cause of morbidity and early mortality in these patients. Increasing evidence suggests that chemo- and immunotherapies can alter the gut microbiome, which is closely linked to immune regulation. Both innate and adaptive immune responses can be shaped by changes in the microbiome. We therefore hypothesise that myeloma treatment–induced alterations to the gut microbiome directly impact immune function and increase susceptibility to infection.

Research Methodology

This PhD project will investigate how myeloma therapies affect the gut microbiome, and how these changes influence immune function and infection risk. The student will assess microbiome alterations in both preclinical mouse models and stool samples collected from patients with myeloma. In parallel, the project will explore how these changes impact immune cell populations and responses to infection. To do this, the PhD student will learn in vivo techniques including animal handling, as well as isolation of primary human samples under ethical approval. The student will receive training in cellular biology methodologies including, DNA isolation, library preparation and sequencing as well as bioinformatic skills to analyse the acquired sequencing data.

The project will be supervised by Dr Hellmich and Prof Rushworth (Norwich Medical School). Dr Hellmich is a clinical researcher with direct access to primary patient samples, while Prof Rushworth has successfully supervised ten PhD students, all of whom progressed to postdoctoral positions. The laboratory provides a supportive and collaborative environment, with weekly lab meetings, journal clubs, and strong encouragement to present at local, national, and international conferences.

This project offers the opportunity to develop advanced research skills in immunology, microbiome science, and bioinformatics, alongside transferable skills essential for future career development.

For information on eligibility and how to apply: http://www.uea.ac.uk/phd/mmbdtp

Entry requirements

At least UK equivalence Bachelors (Honours) 2:1. English Language requirement (MED/SCI equivalent: IELTS 6.5 overall, 6 in each category). 

Mode of study: Full-time

Start date: 1 October 2026

Additional Funding Information 

This project is awarded with a 4-year fully-funded studentship including direct payment of tuition fees to the University, stipend for living expenses (2025/26 rate: £20,780) and a Research Training Support Grant for each year of the studentship.

Advert information